Figure 4 Treponema pallidum invasion

Slides:

Advertisements

Similar presentations

Figure 1 Venomous snakes

Advertisements

Copyright © 2017 American Academy of Pediatrics.

Figure 1. Forest plot: overall estimate

Figure 1 Incidence and mortality of cutaneous melanoma

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomy of the spinal column

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Host damage from infection-related inflammatory

Reproduced with permission from Yancy, C. W. et al. 2017

Figure 2 Systemic immune responses to cryptococcal antigen

Figure 5 BMI and cardiorespiratory fitness levels

Figure 8 Implanted devices for the management of heart failure

Figure 4 BMI and mortality in patients with heart failure

Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room B.A. Cunha Clinical Microbiology and Infection

Figure 2 Three-year survival rates on the basis of body composition

Figure 7 European Society of Cardiology 2016

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 CAR-T-cell design

Figure 8 4D magnetic resonance imaging patterns

Figure 5 Corticosteroid treatment can reduce brain

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Syphilis: The Great Pox

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 6 Imaging methods used to study Parkinson disease

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Figure 1 Health-care system today

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 1 Cardiovascular risk and disease across the life-course

Figure 2 Incidence of multiple myeloma in 2012

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Cardiol. doi: /nrcardio

Structure of grepafloxacin relative to activity and safety profile

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Serum phosphate level is associated with

Figure 2 Logistical requirements for autologous

Figure 1 The VEGF family of growth factors

Figure 8 HRQOL in individuals with RA

This Month in AJKD American Journal of Kidney Diseases

Figure 4 Diagnosing neuropathic pain

Figure 1 Structure of ADAMTS13

A New Era of Renal Denervation Trials for Patients With Hypertension?

Adapted with permission from Tesfaye, S. , Boulton, A. J

This Month in AJKD American Journal of Kidney Diseases

Figure 9 Management of atrial fibrillation

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Global mortality and incidence rates of pancreatic cancer

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Intracellular distribution and

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Global kidney cancer incidence

Figure 7 VEGF as a mediator of neuroinflammatory disease

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Algorithm for the management of hypertension

Figure 1 Treponema pallidum

Figure 4 Clinical manifestations of alopecia areata

Part b is reproduced with permission from Messenger, A. G

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Figure 4 Treponema pallidum invasion Part a is reproduced by permission of Oxford University Press: Riley, B.S. et al., Virulent Treponema pallidum activates human vascular endothelial cells, The Journal of infectious diseases, 1992, 165, 3, 484–493. Part b is reproduced from Cruz, A. R. et al. Immune evasion and recognition of the syphilis spirochete in blood and skin of secondary syphilis patients: two immunologically distinct compartments. PLoS Negl. Trop. Dis. 6, e1717 (2012) Peeling, R. W. et al. (2017) Syphilis Nat. Rev. Dis. Primers doi:10.1038/nrdp.2017.73